CHAIN 1 933 Progesterone receptor.
/FTId=PRO_0000053693.
DNA_BIND 567 639 Nuclear receptor.
ZN_FING 567 587 NR C4-type.
ZN_FING 603 627 NR C4-type.
REGION 1 566 Modulating, Pro-Rich.
REGION 681 933 Steroid-binding.
MOTIF 183 187 Nuclear localization signal (Potential).
MOD_RES 20 20 Phosphoserine.
MOD_RES 81 81 Phosphoserine.
MOD_RES 102 102 Phosphoserine.
MOD_RES 130 130 Phosphoserine.
MOD_RES 162 162 Phosphoserine.
MOD_RES 190 190 Phosphoserine.
MOD_RES 213 213 Phosphoserine.
MOD_RES 294 294 Phosphoserine; by MAPK1.
MOD_RES 345 345 Phosphoserine; by MAPK.
MOD_RES 400 400 Phosphoserine; by CDK2.
MOD_RES 676 676 Phosphoserine.
CROSSLNK 7 7 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO).
CROSSLNK 388 388 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO);
alternate.
CROSSLNK 388 388 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in ubiquitin);
alternate.
CROSSLNK 531 531 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO).
VAR_SEQ 1 164 Missing (in isoform A).
/FTId=VSP_003706.
VARIANT 50 50 A -> T (in dbSNP:rs11571143).
/FTId=VAR_019221.
VARIANT 120 120 A -> V (in dbSNP:rs11571144).
/FTId=VAR_019222.
VARIANT 186 186 P -> L (in dbSNP:rs11571145).
/FTId=VAR_019223.
VARIANT 301 301 M -> R (in dbSNP:rs11571146).
/FTId=VAR_019224.
VARIANT 344 344 S -> T (in dbSNP:rs3740753).
/FTId=VAR_016117.
VARIANT 347 347 C -> S (in dbSNP:rs11571147).
/FTId=VAR_025555.
VARIANT 444 444 A -> S (in dbSNP:rs11571150).
/FTId=VAR_019225.
VARIANT 529 529 V -> L (in dbSNP:rs11571151).
/FTId=VAR_019226.
VARIANT 536 536 Q -> P (in dbSNP:rs11571152).
/FTId=VAR_019227.
VARIANT 625 625 R -> I (in dbSNP:rs2020874).
/FTId=VAR_014627.
VARIANT 651 651 L -> V (in dbSNP:rs11571222).
/FTId=VAR_019228.
VARIANT 660 660 V -> L (in dbSNP:rs1042838).
/FTId=VAR_016118.
VARIANT 865 865 S -> L (in dbSNP:rs2020880).
/FTId=VAR_014628.
MUTAGEN 7 7 K->R: Some loss of sumoylation; when
associated with R-531. Complete loss of
sumoylation; when associated with R-388
and R-531.
MUTAGEN 294 294 S->A: No effect on interaction with
CUEDC2. Impaired progesterone-induced
transcriptional activity. No CUEDC2- nor
progestin-mediated protein degradation.
No change in sumoylation; when associated
with A-344 and A-345.
MUTAGEN 294 294 S->D: Decreases protein stability and
increases progesterone-induced
transcriptional activity.
MUTAGEN 344 344 S->A: No interaction with SP1. No change
in progestin-induced protein degradation;
when associated with A-345. No change in
sumoylation; when associated with A-294
and A-345.
MUTAGEN 345 345 S->A: No change in progestin-induced
protein degradation; when associated with
A-344. No change in sumoylation; when
associated with A-294 and A-344.
MUTAGEN 388 388 K->R: Great loss of sumoylation; when
associated with R-7. Completely abolishes
sumoylation; when associated with R-7 and
R-531. Loss of CUEDC2-mediated protein
degradation. Increased ligand-dependent
transcriptional activity.
MUTAGEN 400 400 S->A: Abolishes CDK2-induced activity in
the absence, but not in the presence, of
progestin. Delayed nuclear translocation
in presence of progestin.
MUTAGEN 531 531 K->R: Some loss of sumoylation; when
associated with R-7. Completely abolishes
sumoylation; when associated with R-7 and
R-388.
CONFLICT 226 226 G -> S (in Ref. 1; CAA36018).
CONFLICT 256 256 V -> S (in Ref. 1; CAA36018).
TURN 568 570
STRAND 576 578
STRAND 581 583
HELIX 585 596
TURN 613 618
HELIX 620 630
HELIX 686 694
HELIX 711 735
HELIX 739 741
HELIX 744 771
STRAND 774 779
STRAND 782 784
HELIX 786 788
HELIX 792 811
HELIX 815 826
STRAND 828 830
HELIX 838 857
HELIX 863 896
HELIX 898 901
HELIX 907 921
STRAND 925 927
Back to Top